Table 1 Clinical characteristics and RadScore of all patients
Characteristic | Cohort I (n = 303) | Cohort II (n = 203) | P value | Genotypes | Training (Cohort I) | Test (Cohort II) | P value |
|---|---|---|---|---|---|---|---|
Age (years) | Â | Â | < 0.001 | EGFR | Â | Â | < 0.001 |
 Mean ± SD | 62.1 ± 10.8 | 67.7 ± 9.5 |  | Mutant | 137 (45.2) | 55 (29.9) |  |
Gender | Â | Â | 0.014 | Wildtype | 166 (54.8) | 129 (70.1) | Â |
 Male | 190 (62.7) | 140 (69.0) |  | 19Del |  |  | < 0.001 |
 Female | 113 (37.3) | 63 (31.0) |  | Mutant | 59 (26.2) | 21 (14.0) |  |
Smoking status | Â | Â | < 0.001 | Wildtype | 166 (73.8) | 129 (86.0) | Â |
 Smoker | 151 (49.8) | 143 (70.4) |  | L858R |  |  | < 0.001 |
 Nonsmoker | 152 (50.2) | 60 (29.6) |  | Mutant | 44 (5.8) | 16 (11.0) |  |
Tumor location | Â | Â | 0.020 | Wildtype | 166 (79.0) | 129 (89.0) | Â |
 RUL | 89 (29.4) | 70 (34.5) |  | T790M |  |  | < 0.001 |
 RML | 27 (8.9) | 19 (9.4) |  | Mutant | 19 (10.3) | 9 (6.5) |  |
 RLL | 53 (17.5) | 35 (17.2) |  | Wildtype | 166 (89.7) | 129 (93.5) |  |
 LUL | 92 (30.4) | 53 (26.1) |  | Immune molecule | Training (Cohort I) | Test (Cohort II) | P value |
 LLL | 42 (13.9) | 26 (12.8) |  | PD-1/PD- L1 |  |  | 0.016 |
LVI | Â | Â | < 0.001 | Positive | 58 (51.3) | 26 (40.0) | Â |
 Present | 120 (39.6) | 43 (21.2) |  | Negative | 55 (48.7) | 39 (60.0) |  |
 Absent | 183 (60.4) | 160 (78.8) |  | RadScore | Training (Cohort I) | Test (Cohort II) | P value |
PI | Â | Â | < 0.001 | 2D region Median (six groups) | (0.051, 0.131, 0.0976, 0.074, -0.004) | (-0.027, -0.119, -0.145, -0.046, -0.066) | < 0.001 |
 Yes | 232 (76.6) | 87 (42.9) |  | ||||
 No | 71 (23.4) | 116 (57.1) |  | 3D region Median (six groups) | (0.050, 0.101, 0.092, 0.178, -0.018) | (0.000, -0.131, -0.023, -0.094, -0.022) | < 0.001 |
T stage | Â | Â | < 0.001 | ||||
 T4 | 100 (33.0) | 25 (12.3) |  | Peritumoral region Median (six groups) | (-0.006, 0.072, 0.039, 0.138, -0.032) | (-0.051, -0.064, -0.056, -0.067, 0.003) | < 0.001 |
 Other | 203 (67.0) | 178 (87.7) |  |